SEC Comment Letter 0000000000-24-013826 to Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc.
Date: Dec. 16, 2024 · CIK: 0001645460 · Accession: 0000000000-24-013826

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-38327

Date

December 16, 2024

Author

Kerri-Ann Millar

Form

UPLOAD

Company

Cue Biopharma, Inc.

Letter

December 16, 2024 Kerri-Ann Millar Chief Financial Officer Cue Biopharma, Inc. 40 Guest Street Boston, MA 02135 Re:Cue Biopharma, Inc. Form 10-K for Fiscal Year Ended December 31, 2023 File No. 001-38327 Dear Kerri-Ann Millar: We have completed our review of your filings. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

December 16, 2024
Kerri-Ann Millar
Chief Financial Officer
Cue Biopharma, Inc.
40 Guest Street
Boston, MA 02135
Re:Cue Biopharma, Inc.
Form 10-K for Fiscal Year Ended December 31, 2023
File No. 001-38327
Dear Kerri-Ann Millar:
            We have completed our review of your filings. We remind you that the company and
its management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io